| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 02/27/2003 | CA2457611A1 Novel molecular target for neurotoxicity |
| 02/27/2003 | CA2457321A1 Combinatorial methods for inducing cancer cell death |
| 02/27/2003 | CA2457143A1 In situ immunization |
| 02/27/2003 | CA2457066A1 Human protooncogene kg-20 and protein encoded therein |
| 02/27/2003 | CA2456340A1 Propagation of human hepatoblastoma cell in non-human animals |
| 02/27/2003 | CA2456334A1 Molecular characteristics of non-small cell lung cancer |
| 02/27/2003 | CA2455827A1 Materials and methods for nerve grafting comprising degrading chondroitin sulfate proteoglycan |
| 02/27/2003 | CA2454756A1 Methods and compounds for the targeting of protein to exosomes |
| 02/26/2003 | WO2002018407A2 Antisense oligonucleotides against vanilloid receptor 1 |
| 02/26/2003 | EP1285967A2 Human retroviral packaging cell line |
| 02/26/2003 | EP1285960A2 Virulence genes from Salmonella typhimurium |
| 02/26/2003 | EP1285942A1 Polypeptide derivatives and nucleic acid carriers containing the same |
| 02/26/2003 | EP1285087A2 Enzymatic assays for screening anti-cancer agents |
| 02/26/2003 | EP1285081A2 Improved methods of transfection |
| 02/26/2003 | EP1285080A2 Method for the purification of alphavirus replicon particles |
| 02/26/2003 | EP1285079A2 Modified bovine adenovirus having altered tropism |
| 02/26/2003 | EP1285078A2 Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids |
| 02/26/2003 | EP1285074A1 Rh116 polypeptides and its fragments and polynucleotides encoding said polypeptides and therapeutic uses |
| 02/26/2003 | EP1285071A2 Novel dual oxidases as mitogenic and endocrine regulators |
| 02/26/2003 | EP1285061A1 Antisense modulation of pten expression |
| 02/26/2003 | EP1285004A1 Synthetic peptides and uses therefore |
| 02/26/2003 | EP1285002A2 REGULATING LIPID LEVELS VIA THE i ZMAX1 /i OR i HBM /i GENE |
| 02/26/2003 | EP1284999A2 Repair of nerve damage |
| 02/26/2003 | EP1284997A2 Therapeutic compounds for ovarian cancer |
| 02/26/2003 | EP1284996A2 Therapeutic anti-melanoma compounds |
| 02/26/2003 | EP1284720A2 Method of treating hepatitis delta viral infection |
| 02/26/2003 | EP0822986B1 Antagonists of human interleukin-6 that are totally incapable of binding gp 130, and their use in the preparation of pharmaceutical compounds |
| 02/26/2003 | EP0770137B1 Improvements in production of proteins in host cells |
| 02/26/2003 | EP0768893B1 Polynucleotide vaccine for papillomavirus |
| 02/26/2003 | CN1399680A 上皮细胞生长抑制剂 Epithelial cell growth inhibitor |
| 02/26/2003 | CN1399679A Altering gene expression with ssDNA produced in vivo |
| 02/26/2003 | CN1399678A Human Enzymes of metalloprotease family |
| 02/26/2003 | CN1399644A Novel human G-Protein coupled receptor |
| 02/26/2003 | CN1399562A Method of treating lupus based on antibody affinity and screening methods and compositions for use thereof |
| 02/26/2003 | CN1398973A Liver cancer targeting hepatitis B antisense RNA expression vector and its construction process and use |
| 02/26/2003 | CN1398639A Application of TIMP-4 gene in preparing medicine for treating cardiac vascular disease and repairing scar clinically |
| 02/26/2003 | CA2420656A1 Antisense oligonucleotides against vanilloid receptor 1 |
| 02/25/2003 | US6525242 Preparation of non-human animals having chimeric livers for use of animal models for human liver toxins; immunocompetent animals are rendered tolerant to human hepatocytes by cell or lysate administration during embryonic or neonate stage |
| 02/25/2003 | US6525184 Self-regulated apoptosis of inflammatory cells |
| 02/25/2003 | US6525178 PGC-1, a novel brown fat PPARgamma coactivator |
| 02/25/2003 | US6525174 Precerebellin-like protein |
| 02/25/2003 | US6525030 Gene delivery to periosteal cells by microneedle injection |
| 02/25/2003 | US6525029 Contacting cell with (i) a recombinant adenoviral vector comprising a transgene and (ii) a recombinant adenoviral vector encoding a TNF receptor fusion protein comprising the extracellular domain |
| 02/25/2003 | US6524856 Use of consensus sequences for targeted homologous gene isolation and recombination in gene families |
| 02/25/2003 | US6524851 Hybrid nucleic acid molecules and vectors including β-globin regulatory elements |
| 02/25/2003 | US6524840 Polynucleotides, host cell expression systems, the encoded proteins, polypeptides and peptides |
| 02/25/2003 | US6524836 Zace1: a human metalloenzyme |
| 02/25/2003 | US6524825 Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins |
| 02/25/2003 | US6524824 Compositions and methods for non-targeted activation of endogenous genes |
| 02/25/2003 | US6524821 Anti-apoptotic compositions comprising the R1 subunit of herpes simplex virus ribonucleotide reductase or its N-terminal portion; and uses thereof |
| 02/25/2003 | US6524819 And their use in the screening for compounds of use in characterization, diagnosis, and treatment of conditions such as Alzheimer's disease, Down syndrome and other forms of dementia |
| 02/25/2003 | US6524818 Compositions and methods for non-targeted activation of endogenous genes |
| 02/25/2003 | US6524815 A promoter which is active in the vascular endothelium and to its use for expressing genes of interest in this tissue |
| 02/25/2003 | US6524813 Novel polynucleotides and polypeptides of the spo0J family derived from Staphylococcus |
| 02/25/2003 | US6524806 Methods of screening for ligands of human hemetopoietin receptor HU-B1.219 |
| 02/25/2003 | US6524802 Methods of detecting growth differentiation factor-14 |
| 02/25/2003 | US6524796 Selecting proteins that binds to said promoter DNA; introducing DNA coding for said proteins into cells carrying a reporter gene; testing for presence of said reporter gene expression product |
| 02/25/2003 | US6524613 Hepatocellular chimeraplasty |
| 02/25/2003 | US6524588 Influenza vaccine |
| 02/25/2003 | US6524582 Methods and compositions for impairing multiplication of HIV-1 |
| 02/25/2003 | US6524573 Epidermal growth factor receptor activity is induced |
| 02/25/2003 | US6524571 Methioninase gene therapy for tumor treatment |
| 02/20/2003 | WO2003014703A2 Nucleic acids, polypeptides, single nucleotide polymorphisms and methods of use thereof |
| 02/20/2003 | WO2003014366A2 Rna amplification system using plant components in animal cells |
| 02/20/2003 | WO2003014359A2 A fusion protein |
| 02/20/2003 | WO2003014342A2 Identification of a dna variant associated with adult type hypolactasia |
| 02/20/2003 | WO2003014338A1 Process for producing inactivated virus envelope |
| 02/20/2003 | WO2003014322A2 Proteins associated with cell growth, differentiation, and death |
| 02/20/2003 | WO2003014318A2 Methods for treating diabetes and other blood sugar disorders |
| 02/20/2003 | WO2003014307A2 Antisense modulation of apolipoprotein(a) expression |
| 02/20/2003 | WO2003014306A2 Antisense modulation of cholesteryl ester transfer protein expression |
| 02/20/2003 | WO2003014153A2 Cellular virus receptors and methods of use. |
| 02/20/2003 | WO2003014152A2 Phosphatidylinositol 5-phosphate-binding proteins |
| 02/20/2003 | WO2003014140A1 Compositions, methods and products comprising human papillomavirus for detecting and treating a cancer |
| 02/20/2003 | WO2003013647A2 Electrodes coated with treating agent and uses thereof |
| 02/20/2003 | WO2003013615A1 Electroporative delivery of molecules to organs |
| 02/20/2003 | WO2003013594A2 Modulation of antibody formation in mammals, applicability in gene therapy and animal model generation |
| 02/20/2003 | WO2003013593A2 Composite superimmunogen for bi-functional vaccine use for the treatment of illnesses associated with a stromal tissue disorder |
| 02/20/2003 | WO2003013577A2 Use of il-18 inhibitors in hypersensitivity disorders |
| 02/20/2003 | WO2003013555A1 Method for amplifying expression from a cell specific promoter |
| 02/20/2003 | WO2003013437A2 Compositions and methods for the prevention and treatment of huntington's disease |
| 02/20/2003 | WO2003013431A2 Compositions and methods for the therapy and diagnosis of breast cancer |
| 02/20/2003 | WO2003013244A1 Oral treatment of hemophilia |
| 02/20/2003 | WO2003000851A3 Method for rapid screening of bacterial transformants and novel simian adenovirus proteins |
| 02/20/2003 | WO2002099138A3 HS2STs AS MODIFIERS OF THE P53 PATHWAY AND METHODS OF USE |
| 02/20/2003 | WO2002099062A3 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use |
| 02/20/2003 | WO2002098900A3 Novel human proteins, polynucleotides encoding them and methods of using the same |
| 02/20/2003 | WO2002098360A3 Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
| 02/20/2003 | WO2002096927A3 Ribozyme based treatment of female reproductive diseases |
| 02/20/2003 | WO2002094862A3 Hypoxia inducible factors and uses thereof for inducing angiogenesis and improving muscular functions |
| 02/20/2003 | WO2002090501A3 Vectors having replication, immunogenicity and/or pathogenicity under stress promoter regulation and use thereof |
| 02/20/2003 | WO2002088323A3 Gene delivery compounds |
| 02/20/2003 | WO2002083080A3 Method of treating arthritis using lentiviral vectors in gene therapy |
| 02/20/2003 | WO2002081628A3 Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
| 02/20/2003 | WO2002081621A3 Vaccine against the nile fever virus |
| 02/20/2003 | WO2002079464A3 Viral vectors |
| 02/20/2003 | WO2002072019A3 Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases |
| 02/20/2003 | WO2002064021A3 Methods and compositions for control of bone formation via modulation of ciliary neurotrophic factor activity |
| 02/20/2003 | WO2002051978A3 Yeasts transformed by genes enhancing their cold stress tolerance |
| 02/20/2003 | WO2002047730A8 Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins |